A53T突触核蛋白帕金森病前驱期和运动期的5-羟色胺能病理与疾病负担:横断面研究
该横断面研究纳入14例A53T SNCA突变携带者、25例健康对照和25例特发性帕金森病患者,用[11C]DASB PET定量5-羟色胺转运体密度。结果显示前驱期携带者已在腹侧和背侧中缝核等区域出现结合潜能降低,且脑干降低与MDS-UPDRS总分相关。结论提示5-羟色胺能病理早于多巴胺能病理和运动症状,并与疾病负担相关。
要点
- A53T携带者前驱期已出现中缝核等区域5-羟色胺转运体结合降低。
- 前驱期5-羟色胺能病理对应Braak 1-3期,早于多巴胺能缺损。
- 脑干5-羟色胺转运体降低与MDS-UPDRS总分呈负相关。
核心结论
- 前驱期A53T SNCA携带者的5-羟色胺能病理先于多巴胺能病理和运动症状出现,并与疾病负担相关。
研究设计与样本
- 横断面研究,从希腊雅典和意大利萨莱诺的运动障碍专科门诊招募14例A53T SNCA突变携带者。
- 纳入25例无神经或精神疾病个人及家族史的健康对照,年龄与携带者匹配。
- 纳入25例特发性帕金森病患者(队列1),并检索另一扫描仪扫描的40例特发性帕金森病患者数据(队列2)。
- 用[11C]DASB PET非可置换结合潜能定量5-羟色胺转运体密度,并构建反映Braak 1-6期的脑地形图作为种子图。
- 所有参与者接受临床评估、[123I]FP-CIT SPECT评估纹状体多巴胺转运体结合及MRI体积分析。
主要发现
- 14例A53T携带者中7例(50%) confirmed有运动症状并确诊帕金森病,另7例(50%) confirmed无运动症状(前驱期),其[123I]FP-CIT SPECT confirmed无纹状体多巴胺能缺损。
- 与健康对照相比,前驱期A53T携带者在腹侧中缝核(p<0·0001)、背侧中缝核(p=0·0002)、尾状核(p=0·00015)、壳核(p=0·036)、丘脑(p=0·00074)、下丘脑(p<0·0001)、杏仁核(p=0·0041)和脑干(p=0·046)显示[11C]DASB非可置换结合潜能降低。
- 伴帕金森病的A53T携带者上述降低扩展至海马(p=0·0051)、前扣带回(p=0·022)和后扣带回(p=0·036)、岛叶(p=0·0051)、额叶(p=0·0016)、顶叶(p=0·019)、颞叶(p<0·0001)和枕叶(p=0·0053)皮层。
- 伴帕金森病的A53T携带者与健康对照相比纹状体[123I]FP-CIT特异性结合比降低(p<0·0001)。
- 前驱期A53T携带者的[11C]DASB非可置换结合潜能降低见于对应Braak 1-3期的脑区,而对应Braak 4-6期的脑区大部分保留;除1例过去一年确诊帕金森病的参与者外,所有伴帕金森病的A53T携带者对应Braak 1-6期的脑区[11C]DASB非可置换结合潜能均降低。
临床怎么用
- 5-羟色胺转运体分子影像有望在体内可视化帕金森病前驱期病理。
- 未来可探索5-羟色胺转运体成像作为筛查和监测进展的辅助工具,补充多巴胺能成像。
- 5-羟色胺转运体成像或可作为临床试验中帕金森病负担的标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Because of the highly penetrant gene mutation and clinical features consistent with idiopathic Parkinson's disease, carriers of the autosomal dominant Ala53Thr (A53T; 209G→A) point mutation in the α-synuclein (SNCA) gene are an ideal population to study the premotor phase and evolution of Parkinson's pathology. Given the known neurochemical changes in the serotonergic system and their association with symptoms of Parkinson's disease, we hypothesised that carriers of the A53T SNCA mutation might show abnormalities in the serotonergic neurotransmitter system before the diagnosis of Parkinson's disease, and that this pathology might be associated with measures of Parkinson's burden. METHODS: In this cross-sectional study, we recruited carriers of the A53T SNCA mutation from specialist Movement Disorders clinics in Athens, Greece, and Salerno, Italy, and a cohort of healthy controls with no personal or family history of neurological or psychiatric disorders from London, UK (recruited via public advertisement) who were age matched to the A53T SNCA carriers. We also recruited one cohort of patients with idiopathic Parkinson's disease (cohort 1) from Movement Disorders clinics in London, UK, and retrieved data on a second cohort of such patients (cohort 2; n=40) who had been scanned with a different scanner. 7-day continuous recording of motor function was used to determine the Parkinson's disease status of the A53T carriers. To assess whether serotonergic abnormalities were present, we used [11C]DASB PET non-displaceable binding to quantify serotonin transporter density. We constructed brain topographic maps reflecting Braak stages 1-6 and used these as seed maps to calculate [11C]DASB non-displaceable binding potential in our cohort of A53T SNCA carriers. Additionally, all participants underwent a battery of clinical assessments to determine motor and non-motor symptoms and cognitive status, and [123I]FP-CIT single-photon emission CT (SPECT) to assess striatal dopamine transporter binding and MRI for volumetric analyses to assess whether pathology is associated with measures of Parkinson's disease burden. FINDINGS: Between Sept 1, 2016, and Sept 30, 2018, we recruited 14 A53T SNCA carriers, 25 healthy controls, and 25 patients with idiopathic Parkinson's disease. Seven (50%) of 14 A53T SCNA carriers were confirmed to have motor symptoms and confirmed to have Parkinson's disease, and the absence of motor symptoms was confirmed in seven (50%) A53T SCNA carriers (ie, premotor), in whom [123I]FP-CIT SPECT confirmed the absence of striatal dopaminergic deficits. Compared with healthy controls, premotor A53T SNCA carriers showed loss of [11C]DASB non-displaceable binding potential in the ventral (p<0·0001) and dorsal (p=0·0002) raphe nuclei, caudate (p=0·00015), putamen (p=0·036), thalamus (p=0·00074), hypothalamus (p<0·0001), amygdala (p=0·0041), and brainstem (p=0·046); and in A53T SNCA carriers with Parkinson's disease this loss was extended to the hippocampus (p=0·0051), anterior (p=0·022) and posterior cingulate (p=0·036), insula (p=0·0051), frontal (p=0·0016), parietal (p=0·019), temporal (p<0·0001), and occipital (p=0·0053) cortices. A53T SNCA carriers with Parkinson's disease showed a loss of striatal [123I]FP-CIT-specific binding ratio compared with healthy controls (p<0·0001). Premotor A53T SNCA carriers had loss of [11C]DASB non-displaceable binding potential in brain areas corresponding to Braak stages 1-3, whereas [11C]DASB non-displaceable binding potential was largely preserved in areas corresponding to Braak stages 4-6. Except for one participant who was diagnosed with Parkinson's disease in the past year, all A53T SNCA carriers with Parkinson's disease had decreases in [11C]DASB non-displaceable binding potential in brain areas corresponding to Braak stages 1-6. Decreases in [11C]DASB non-displaceable binding potential in the brainstem were associated with increased Movement Disorder Score-Unified Parkinson's Disease Rating Scale total scores in all A53T SNCA carriers (r -0·66, 95% CI -0·88 to -0·20; p=0·0099), idiopathic Parkinson's disease cohort 1 (r -0·66, -0·84 to -0·36; p=0·00031), and idiopathic Parkinson's disease cohort 2 (r -0·71, -0·84 to -0·52; p<0·0001). INTERPRETATION: The presence of serotonergic pathology in premotor A53T SNCA carriers preceded development of dopaminergic pathology and motor symptoms and was associated with disease burden, highlighting the potential early role of serotonergic pathology in the progression of Parkinson's disease. Our findings provide evidence that molecular imaging of serotonin transporters could be used to visualise premotor pathology of Parkinson's disease in vivo. Future work might establish whether serotonin transporter imaging is suitable as an adjunctive tool for screening and monitoring progression for individuals at risk or patients with Parkinson's disease to complement dopaminergic imaging, or as a marker of Parkinson's burden in clinical trials. FUNDING: Lily Safra Hope Foundation and National Institute for Health Research (NIHR) Biomedical Research Centre at King's College London.
引用
- Wilson H, Dervenoulas G, Pagano G, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019. PMID: 31229470. doi:10.1016/S1474-4422(19)30140-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。